Elizabeth Anderson
Stock Analyst at Evercore ISI Group
(1.99)
# 1,520
Out of 4,667 analysts
97
Total ratings
36.96%
Success rate
-5.83%
Average return
Main Sectors:
Stocks Rated by Elizabeth Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WAY Waystar Holding | Maintains: Outperform | $32 → $36 | $31.23 | +15.27% | 4 | Nov 7, 2024 | |
| MCK McKesson | Maintains: Outperform | $560 → $680 | $615.65 | +10.45% | 4 | Nov 7, 2024 | |
| ALGN Align Technology | Maintains: Outperform | $270 → $250 | $222.58 | +12.32% | 11 | Oct 24, 2024 | |
| WBA Walgreens Boots Alliance | Maintains: In-Line | $7.5 → $10 | $8.29 | +20.63% | 12 | Oct 16, 2024 | |
| XRAY DENTSPLY SIRONA | Maintains: Outperform | $29 → $27 | $18.88 | +43.01% | 6 | Oct 8, 2024 | |
| TDOC Teladoc Health | Maintains: In-Line | $8 → $9 | $8.93 | +0.78% | 2 | Oct 8, 2024 | |
| IQV IQVIA Holdings | Maintains: Outperform | $270 → $265 | $191.33 | +38.50% | 5 | Oct 8, 2024 | |
| HCAT Health Catalyst | Maintains: Outperform | $8 → $10 | $7.54 | +32.63% | 5 | Oct 8, 2024 | |
| FTRE Fortrea Holdings | Maintains: In-Line | $22 → $20 | $18.68 | +7.07% | 6 | Oct 8, 2024 | |
| DOCS Doximity | Maintains: In-Line | $34 → $45 | $51.53 | -12.67% | 7 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $62 → $75 | $55.77 | +34.48% | 5 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $7 → $4 | $1.59 | +151.57% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $250 → $240 | $236.23 | +1.60% | 3 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $23 | $20.26 | +13.52% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: In-Line | $165 | $161.16 | +2.38% | 2 | Aug 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $105 → $115 | $118.33 | -2.81% | 5 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $21.11 | -5.26% | 3 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $12 → $16 | $14.31 | +11.81% | 2 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $68 → $26 | $11.24 | +133.54% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $35 → $15 | $4.85 | +209.28% | 3 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 | $2.52 | +336.51% | 2 | Jan 4, 2022 |
Waystar Holding
Nov 7, 2024
Maintains: Outperform
Price Target: $32 → $36
Current: $31.23
Upside: +15.27%
McKesson
Nov 7, 2024
Maintains: Outperform
Price Target: $560 → $680
Current: $615.65
Upside: +10.45%
Align Technology
Oct 24, 2024
Maintains: Outperform
Price Target: $270 → $250
Current: $222.58
Upside: +12.32%
Walgreens Boots Alliance
Oct 16, 2024
Maintains: In-Line
Price Target: $7.5 → $10
Current: $8.29
Upside: +20.63%
DENTSPLY SIRONA
Oct 8, 2024
Maintains: Outperform
Price Target: $29 → $27
Current: $18.88
Upside: +43.01%
Teladoc Health
Oct 8, 2024
Maintains: In-Line
Price Target: $8 → $9
Current: $8.93
Upside: +0.78%
IQVIA Holdings
Oct 8, 2024
Maintains: Outperform
Price Target: $270 → $265
Current: $191.33
Upside: +38.50%
Health Catalyst
Oct 8, 2024
Maintains: Outperform
Price Target: $8 → $10
Current: $7.54
Upside: +32.63%
Fortrea Holdings
Oct 8, 2024
Maintains: In-Line
Price Target: $22 → $20
Current: $18.68
Upside: +7.07%
Doximity
Oct 8, 2024
Maintains: In-Line
Price Target: $34 → $45
Current: $51.53
Upside: -12.67%
Oct 8, 2024
Maintains: Outperform
Price Target: $62 → $75
Current: $55.77
Upside: +34.48%
Oct 8, 2024
Maintains: In-Line
Price Target: $7 → $4
Current: $1.59
Upside: +151.57%
Sep 24, 2024
Maintains: In-Line
Price Target: $250 → $240
Current: $236.23
Upside: +1.60%
Sep 23, 2024
Maintains: Outperform
Price Target: $18 → $23
Current: $20.26
Upside: +13.52%
Aug 28, 2024
Reinstates: In-Line
Price Target: $165
Current: $161.16
Upside: +2.38%
Aug 15, 2024
Maintains: In-Line
Price Target: $105 → $115
Current: $118.33
Upside: -2.81%
Jul 9, 2024
Maintains: Outperform
Price Target: $23 → $20
Current: $21.11
Upside: -5.26%
Feb 28, 2024
Downgrades: In-Line
Price Target: $12 → $16
Current: $14.31
Upside: +11.81%
Mar 16, 2022
Maintains: In-Line
Price Target: $68 → $26
Current: $11.24
Upside: +133.54%
Mar 2, 2022
Downgrades: In-Line
Price Target: $35 → $15
Current: $4.85
Upside: +209.28%
Jan 4, 2022
Downgrades: In-Line
Price Target: $11
Current: $2.52
Upside: +336.51%